Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 10/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MOGAT2 | Q3SYC2 | 6/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093258 | 1.00 | CCR9 (0.38) | CCR9TP53MOGAT2HSD17B2SCN5A | |
| SCHEMBL1094639 | 0.95 | TP53 (0.40) | CCR9TP53MOGAT2HSD17B2GAA | |
| SCHEMBL1094513 | 0.92 | HSD17B2 (0.40) | CCR9TP53HSD17B2GAAMAPT | |
| SCHEMBL1094065 | 0.84 | HSD17B2 (0.43) | CCR9TP53HSD17B2GAAMAPT | |
| SCHEMBL1095017 | 0.84 | TP53 (0.40) | CCR9TP53MOGAT2HSD17B2 | |
| SCHEMBL1094403 | 0.82 | HSD17B2 (0.41) | CCR9TP53HSD17B2GAAMAPT | |
| SCHEMBL1094687 | 0.82 | TP53 (0.45) | CCR9TP53MOGAT2HSD17B2SMN1; SMN2 | |
| SCHEMBL1093687 | 0.82 | HSD17B2 (0.44) | CCR9HSD17B2 | |
| SCHEMBL1095006 | 0.82 | TP53 (0.43) | CCR9TP53MOGAT2HSD17B2 | |
| SCHEMBL1093618 | 0.82 | CCR9 (0.37) | CCR9TP53MOGAT2HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481579-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | claimed |
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-06-28 | — | — | US | claimed |
| US-8153818-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2012-04-10 | — | — | US | claimed |
| EP-2046762-B1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX INC (US) | 2011-02-16 | — | — | EP | claimed |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-07-29 | — | — | US | claimed |
| EP-2046762-A2 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | ChemoCentryx Inc (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | claimed |
| WO-2008010934-A2 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-8481579-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153818-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2046762-B1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX INC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-2046762-A2 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | ChemoCentryx Inc (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| WO-2008010934-A2 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165303-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | CCR9 1/4885TP53 3275/4885MOGAT2 2178/4885 |
| US-20100190762-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | CCR9 1/4885TP53 3275/4885MOGAT2 2178/4885 |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | CCR9 1/4885TP53 3275/4885MOGAT2 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.